|
|
|
08.04.26 - 04:06
|
Global drug makers face pricing pressure as China targets affordable healthcare (SCMP)
|
|
|
Global pharmaceutical companies posted mixed earnings in China last year, with some firms warning that 2026 will be another tough year as Beijing pushes for affordable healthcare through price bargains.
Multinational corporations (MNCs) with innovative drug pipelines and the ability to quickly address unmet medical needs were expected to outperform rivals relying on mature and off-patent products this year, according to Bruce Liu, senior partner at global consulting firm Simon-Kucher.
His......
|
|
|
|
|
|
|
|
|
|
|
07.04.26 - 05:31
|
Krankenkassen: ′Lieber etwas teureres Bier und Zigaretten′ (DPA-AFX)
|
|
|
BERLIN (dpa-AFX) - Höhere Steuern auf Tabak und Alkohol wären aus Sicht der Krankenkassen sinnvoll. "Lieber etwas teureres Bier und Zigaretten als die milliardenteuren Folgeerkrankungen vom Trinken und Rauchen", sagte der Chef des GKV-Spitzenverbands, ......
|
|
|
|
|
|
|
07.04.26 - 02:06
|
Stricter Chinese scrutiny of offshore vehicles a blow for tech and biotech IPO candidates (SCMP)
|
|
|
US dollar-denominated funds could face more hurdles when investing in Chinese tech and biotech companies as Beijing adopts a stricter approach to companies seeking listings via offshore incorporated vehicles.
Indicative of Chinese regulators' caution in overseeing sensitive industries, industry sources say the move ensures that any sale of assets does not escape regulatory scrutiny.
And for any offshore incorporated structures that are approved, the stock regulator requires listing applicants to......
|
|
|
06.04.26 - 22:15
|
Wie Franklin Biotech-Chancen gezielt nutzt (Fundresearch)
|
|
|
Mit einem klar strukturierten Bottom-up-Ansatz und tiefgehender wissenschaftlicher Analyse identifiziert Fondsmanager Evan McCulloch im Franklin Biotechnology Discovery Fund gezielt unterbewertete Biotech-Unternehmen. In einem Markt, der von Innovationsschüben, M&A-Dynamik und Bewertungsunterschieden geprägt ist, setzt der Fonds auf eine ausgewogene Mischung aus wachstumsstarken Small Caps und stabilen Large Caps – und eröffnet Anlegern so attraktive Chancen im globalen Biotechnologiesektor....
|
|
|
06.04.26 - 21:21
|
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants (ZeroHedge)
|
|
|
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Authored by Ben Sellers via Headline USA,
Two of the major pharmaceutical companies connected with the controversial COVID vaccines were forced to abandon a new research study after failing to garner enough participants.
Pfizer and German vax maker BioNTech had sought to research an updated version of the vaccine in adults ages 50 to 64, but were unable to generate the data needed due to the low enrollment in the trials, Reuters reported.
The study was needed in order to meet new guidelines imposed by the Food and Drug Administration that require the pharmaceutical companies to provide data on the efficacy of the vaccine in comparison with a placebo.
However, it marks a peculiar coda to the pandemic era, when mass formation psychosis swept the globe forcing individuals to forgo their civil liberties en masse and to inject the experimental, gene-altering serum into their DNA under extreme social duress.
Since ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
